Draft WHO Pediatric ARV Guidelines Revision Summary 10/23/05 Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute.

Slides:



Advertisements
Similar presentations
TB & HIV Infection: Treatment
Advertisements

Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere January 2006.
Challenges to Pediatric Antiretroviral Treatment Elaine Abrams, David Hoos MTCT-Plus.
Indicators for monitoring ARV treatment outcomes.
Group Work Recommendations-When to Start Group C.
Starting children and infants on ART; what do the guidelines say? Dr Siobhan Crowley Paediatric & Family HIV Care Department of HIV/AIDS World Heath Organization,
The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.
Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
Prescription and Use of Paediatric Antiretroviral Drugs (ARVs) for the Treatment of HIV in Children.
Changing Therapy Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents published October 2006 AETC NRC Slide Set.
P1060 commentary Philippa Musoke MBChB Makerere University –Johns Hopkins University Research Collaboration, Kampala Uganda.
Accomplishments Year 1 Encouraged HIV testing counseling with referrals to Phidisa 1 Education of Nursing Staff on Pediatric Wards Lectures to Medical.
Thailand New National Guideline for PMTCT 2010 Suchat Hongsiriwon, MD Department of Pediatrics Chonburi Hospital.
WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
Pediatric HIV Care & Treatment in Uganda A Five-Day Training Course For Health Professionals.
KITSO AIDS Training Program
Inputs to a case-based HIV surveillance system. Objectives  Review HIV case definitions  Understand clinical and immunologic staging  Identify the.
ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.
1 KITSO AIDS Training Program Lecture 5: Pediatric Specific Issues and ARV Dosing delivered by Dr. Elizabeth D. Lowenthal Botswana-Baylor Children’s Clinical.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
WHO technical recommendations on pediatric HIV care Summary of revised recommendations on diagnosis, clinical staging & immunological classification, &
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
Clinical Tracking and Management of HIV-Positive Children National Pediatric HIV Training 1.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
1 Advantages and risks for a child to be exposed to the triple prophylaxis during pregnancy and breastfeeding What is the best for the child ? Pr C. Courpotin.
1 Antiretroviral Therapy in HIV-infected Children HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
UK-CAB Jan05 BHIVA treatment guidelines UK-CAB - 28 Jan 2005 Simon Collins, HIV i-Base.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Crossroads Hotel 7 th January  All adolescents & adults with HIV infection & CD4 counts less than/equal to 350 cells/mm3, including pregnant women,
Indications for Initiation of ARV Therapy in Children Age >1 Year Clinical Category CD4 + Cell Percentage Plasma HIV RNA Copy Number Recommendation AIDS.
Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
Regimen Selection to Support a “Public Health” Approach Anthony Amoroso, MD Assistant Professor of Medicine University of Maryland School of Medicine Institute.
1 Monitoring The Patient on ARV Treatment HAIVN Harvard Medical School AIDS Initiative in Vietnam.
ICASA IAS Scaling up Treatment Delivery Programmes: Issues, Challenges & Best Practices Siobhan Crowley HIV Department WHO Geneva.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
8èmes Rencontres Nord-Sud Avelin Aghokeng IRD-UMI233 & University of Montpellier I Yaoundé-Cameroon Avelin Aghokeng IRD-UMI233 & University of Montpellier.
ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.
Access to Paediatric ARV Formulations Provisions for Children.
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.
11 INTRODUCTION TO ANTIRETROVIRAL THERAPY (ART) IN CHILDREN: INITIATION AND MONITORING HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
A Call to Action Children – The missing face of AIDS.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
January 2006 Access to Paediatric ARV formulations Access to Paediatric ARV Formulations The plight of Children.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.
Maternal Toxicity Management
Switch to PI/r monotherapy
Maternal Toxicity Management
Providing ARVs to children in resource limited settings
Maternal Toxicity Management
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
What’s New in the Perinatal Guidelines
Rationale: 2nd Line Regimens in Adults
EVALUATION OF ANTIRETROVIRAL THERAPY FOLLOWED BY AN EDUCATIONAL INTERVENTION TO INCREASE APPROPRIATE USE IN ZIMBABWE.
St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom
Charles Gilks HIV Department, WHO
Anthony D Harries Ministry of Health, Malawi
Presentation transcript:

Draft WHO Pediatric ARV Guidelines Revision Summary 10/23/05 Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute of Child Health and Human Development National Institutes of Health Department of Health and Human Services

Considerations in Revision Stand-alone guidelines for children (in 2003, children incorporated into adult guidelines). Guidelines evidence-based but public health oriented: simple, standardized. Any revisions should enable treatment of a child before they develop severe disease. To better identify risk of severe disease, may need to increase the number of age-related CD4 risk thresholds. Use of new WHO pediatric staging to guide starting therapy, monitoring treatment. Need advocacy for early infant diagnosis; advocacy for pediatric formulations; simplified weight-band based dosing tables.

When to Start Antiretroviral Therapy? In adults: defer for as long as possible without clinical deterioration or compromising immunological response… For children, considerations include that: –Highest mortality in children <18 mo/o. –Inability to diagnose infection <18 mo/o is major problem for treatment. Need to start ARV in exposed child <18 mo (need verify infection status at 18 mo). –Response to ART –ART availability for different ages –Family, social, adherence aspects No randomized evidence

Changes to Pediatric Guidelines: When to Start Changed age-related CD4/TLC values from two to four age categories (based on HPPCMS data). Incorporated new ped HIV staging system into decisions: –Staging and recommendations for ART: Stage 4: treat all regardless of lab Stage 3: treat all regardless of lab (except if child >18 mos and CD4 available, use CD4 guided decision for TB, LIP, OHL, low plts) Stage 2: CD4 or TLC guided decision Stage 1: treat only if CD4 available for decision

When to Start ARVs in Children <18 mos>18 mos Stage 4*CD4All No CD4All Stage 3*CD4AllAll (except TB**, OHL, LIP, thrombocytopenia, where do CD4 guided) No CD4AllAll** Stage 2CD4CD4 guided No CD4TLC guided Stage 1CD4CD4 guided No CD4Do not rx * Stabilize any OI before initiate ARV ** Pulmonary TB: Eval CD4 (if avail)/clinical status after several wks TB rx to decide if need ARV and if so, when ARV start in relation to TB rx

Draft WHO Age-Related CD4 and TLC values for Antiretroviral Treatment Decisions in Children Start ARV When CD4% or Count is + : <11 mo1 yr - <3 yr3 yr - <5 yr>5 yr CD4%* <25%<20%<15% CD4 count* <1,500<750<350<200 *CD4% preferred in children 5 years. If CD4 Assay Not Available, Start ARV When TLC Is + : <11 mos1yr - <3yr3yr - <5 yr>5 yr TLC <4,000<3,000<2,500<1,500 + ART should be started at these levels regardless clinical stage

12-Month Risk of Death By Age and TLC or CD4% HIV Pediatric Prognostic Marker Collaborative Study 3-5 yr 2, yr 3,000 <1 yr 4,000 >5 yr 1,500 5% Total Lymphocyte Count CD4% 5% <1 yr 25% 1-3 yr 20% >3 yr 15%

Age (yrs)5% Risk of Death CD4%CD4 count , Age-Related CD4 Absolute Count Associated With 5% Risk of Death Within 12 Months

Age (years) 12-Month Mortality Risk, Selected CD4%/Count and TLC Age Thresholds HIV Pediatric Prognostic Marker Collaborative Study (Dunn et al) CD4%<25 (<1yr), <20% (1 to <3 yrs), <15% (3 to <5 yrs), <15% (≥ 5 yrs) TLC<4000 (<1yr), <3000 (1 to <3 yrs), <2500 (3 to <5 yrs), <1500 (≥ 5 yrs) CD4<1500 (<1yr), <750 (1 to <3 yrs), <350 (3 to <5 yrs), <200 (≥ 5 yrs)

Changes to Pediatric Guidelines: What to Start ARV choice problem is lack pediatric formulations and lack of dose information for some ARV/ages. –Excludes TFV 1 st line therapy for children (no formulation, dose not defined, safety unclear) as opposed to adult recs. Add ABC to 1 st line NRTIs as virologically superior to AZT/3TC (PENTA), and to begin to get away from d4T (did not want to completely change recs as countries just starting roll-out). Drugs: –Dual NRTI: combination of AZT or d4T or 3TC or ABC (do not use AZT/d4T; possible combos AZT/3TC, d4T/3TC, AZT/ABC, 3TC/ABC, d4T/ABC). –plus NNRTI – prefer NVP if 3 yrs. 2 nd line: Continue 3TC re: decreased viral fitness? Weight-band based dosing tables (underway).

Changes to Pediatric Guidelines: What to Start Issue of infant PMTCT exposure and resistance: –Resistance develops in mom pre- or during pregnancy, IP, PP while BF; transmits to infant. –Resistance developing infant during infant prophylaxis component. Important to note that not all failures of PMTCT are due to resistance (majority not resistant). Current rec: Children with prior NVP or 3TC prophylaxis should be eligible for HAART, including NNRTI regimen and not denied access to life-saving therapy. Studies ongoing/to start in kids to address response to NNRTI therapy post SD NVP exposure. Since no new data and studies pending, no change recommended to current language.

ARV REGIMENS for Pediatric Patients 1 st Line ARVConsiderations2 nd Line ARV Dual NRTI (choose 2, except do not use AZT/d4T) 3TC or AZT [d4T] Minimal toxicity Anemia Lipodystrophy/lactic acidosis/ peripheral neuropathy ddI (+ 3TC?) ABC (+ 3TC?) or ABC Hypersensitivity reactionAZT (+ 3TC?) PLUS NNRTI (choose 1, see age preference) NVP or Prefer <3 yr (<10kg) LPV/r or SQV/r or SQV/NFV or NFV EFVPrefer >3 yr (>10 kg) LPV/r or SQV/r or SQV/NFV or NFV

Alternative ARV Choices for Pediatric Patients 1 st Line ARVConsiderations2 nd Line ARV 3 NRTI Combo (choose 3 except do not use AZT/d4T): NRTI : 3TC or AZT [d4T] Minimal toxicity Anemia Lipodystrophy/lactic acidosis/ peripheral neuropathy ddI (+ 3TC?) or ABC Hypersensitivity reaction PLUS a PI: LPV/r or SQV/r or SQV/NFV or NFV* PLUS an NNRTI: NVP or EFV

Example of Weight-Based Dosing Table for Children Including Pediatric and Adult Formulations Weight (kg) Nevirapine syrupNevirapine tablets Lead-in dose Weeks 1 & 2 syrup (10mg/ml) Full Dose syrup (10mg/ml) Lead-in dose Weeks 1 & 2 200mg tablets Full Dose 200mg tablets ½ am only½ am and pm am or ½ am or pm1 am and ½ pm ½ am and pm1 am and pm am and pm

Changes to Ped Guideline: Monitoring Before and While On ARVs Monitoring: –Primarily clinical-based. –Importance of weight gain/maintenance in clinical evaluation. –Encourage increased use CD4. –Do not use TLC to monitor therapy (only for start). –AZT – baseline Hb suggested and recheck at ~8 weeks. –Symptom-directed for other lab tests.

Baseline and Monitoring Pediatric ARV BaselineOn ARV Confirm dxN/A Clinical stage ReadinessAdherence Concom conditions/meds Wt, ht, developWt, Ht, growth, development Nutritional status CD4 (desirable not required)CD4 q 6-12 mos (or clinical indic) Hb (esp if on AZT)Hb (WBC) 1-3 mos post start ARV, then Sx directed Other labSx-directed, eg ALT, lipid, glucose VL if availableVL if indicated (to confirm CD4 drop?)

Changes to Ped Guidelines: Toxicity Management Improve description of toxicity in children. Outline temporal issues (early vs late). Immediate, life-threatening: Stop all drugs. Once resolves, restart with substitute for offending drug. –Staggered stopping if NNRTI? Non-life threatening: –Continue ARV if can, if mild or moderate. –If severe, switch one offending drug (within class substitution usually) without stop. Late toxicity, such as lipodystrophy: –Management – could change d4T to AZT. Include more details on management/algorithm?

Changes to Ped Guidelines: When to Switch for Treatment Failure Important to check adherence before change. Must have adequate trial ARVs (eg, >6 mos). Before change for growth failure, need assure adequate nutrition, treatment OIs (esp, TB). Algorithm development? –Before change, must check adherence, nutrition, resolution TB/acute OI. Use new clinical staging for decisions? –New or recurrent Stage 3 or 4: change. –New or recurrent Stage 3 (selected conditions?): consider change? If use CD4 criteria, need repeat value before change (also clinical status important in decision).

Changes to Ped Guidelines: When to Switch When Switch for Treatment Failure: –Clinical criteria (if keep selected selected clinical criteria vs use of pediatric clinical staging): Lack/decline in growth –Weight most important –Must be sure unexplained (eg, in presence of adequate nutrition, treated TB, etc). Loss developmental milestones/ encephalopathy New or recurrent OI –Must differentiate from IRS

Changes to Ped Guidelines: When to Switch When Switch for Treatment Failure: –CD4 criteria: If only CD4 and no symptoms, may decide not to change. Viral load monitoring may be useful in this situation (confirm significance). If after reasonable trial of therapy (eg, after 6 months of therapy), switch if CD4 not above or if declines to age-related threshold for initiation of therapy (considering clinical status). Include a % change from peak? Does baseline value matter? Absence of any concurrent conditions that can be associated with lowered CD4.

Potential Proposal to Use Clinical Staging to Decide on Switch Due to Treatment Failure Clinical stageConsiderations 1No switch 2 new or recurrent Consider adherence Monitor closely clinical 3 new or recurrent Check adherence Rx/manage coinfection/OI (eg, TB #) Nutritional issues if growth criteria Consider regimen switch 4 new or recurrent Check adherence Rx/manage coinfection/OI (eg, TB) Nutritional issues if growth criteria Switch regimen # TB may not indicate treatment failure

Changes to Ped Guidelines: TB and ARV TB and ARV: –Drug interactions especially problem in kids due to lack pediatric ARV formulation/drug dosing younger kids, so not many choices. –Need emphasize case detection (child with TB may reflect TB in household not necessarily immune suppression). –TB diagnosis difficulty in kids, most often empiric therapy issue (dx TB if respond to TB treatment). –All kids with pulmonary TB should be CONSIDERED for ARV (stage III). –CD4 thresholds used to determine overall need for start ARV in child with pulmonary TB are as per “when to start” thresholds.

Changes to Ped Guidelines: TB and ARV TB and ARV: –Importance of clinical response to TB rx in determining when ARV start in relation to TB rx (or whether to start ARV if no CD4 available). –When start ARV if pulmonary TB in child? Stabilize TB before make decisions ARV (response first few weeks of TB rx): –If respond well to TB rx, defer ARV until complete TB rx. –If not respond after initial TB rx, start ARV. –Where does CD4 fit in this determination? Adult group will have CD4 gradation to determine when to start ARV in pt with TB (<200 start ARV 2wk-2 mos of TB rx; defer till complete TB rx). Should we have this for children and, if so, what thresholds?

Changes to Ped Guidelines: TB and ARV TB and ARV: –What ARV to start (or to change if on 1 st line) if on rifampin: If <3 yrs: –Triple NRTI (eg, AZT/3TC/ABC) (TFV role?) vs –NVP-based ARV: »Adult group may say continue NVP- based therapy if no other options are available. If >3 yrs: –EFV-based (no dose increase)

Changes to Ped Guidelines: TB and ARV TB and ARV: –If on 2 nd line therapy: If have failed NNRTI, then is now receiving boosted PI, which is “contraindicated” with rifampin. Stop PI and use triple NRTI including TFV if age-appropriate (dose/formulation issues; can’t give with concurrent ddI). Adult group says could still use boosted PI (LPV/r or SQV/r; SQV/NFV?) but with increased monitoring (LFT) who concurrent boosted PI and rifampin rx. Adult group to advocate for availability of rifabutin (then can give boosted PI or NNRTI).

Changes to Ped Guidelines: Adherence Adherence: –Two types problems Program level (cost, formulations, supply) –Reduce cost/free drug –Reliable supply – forecasting needs –Pediatric formulation needs Individual level –Discuss challenges in children, how to maximize »Education, pro-active approach »Reduce pill burden »Disclosure »DOT/outreach/community »Family focused care

Other suggested changes to Ped Guidelines: Treatment interruptions: –Not enough information to make recommendations on this Adolescent section: –Discuss EFV issues in adolescent girls, contraception –Deal with transition to adult care Salvage: –Not enough info ped drugs, needs individualization HBV/HCV coinfection: –Will be some discussion in adult guidelines; should ped cover as well?